- Home
- EDF vs WHWK Comparison
EDF vs WHWK Comparison
Compare EDF & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDF | WHWK |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 179.8M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDF | WHWK |
|---|---|---|
| Price | $5.02 | $3.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 230.3K | 169.7K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.14 | $1.39 |
| 52 Week High | $5.34 | $4.40 |
Technical Indicators
Market Signals| Indicator | EDF | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 55.92 |
| Support Level | $4.95 | $1.84 |
| Resistance Level | $5.04 | $3.77 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 48.39 | 40.26 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.